Barclays resumed coverage on Medtronic with a new price target
$MDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/21/2026 | $84.00 | Neutral | Goldman |
| 2/13/2026 | $116.00 | Overweight | Barclays |
| 2/9/2026 | $121.00 | Hold → Buy | Needham |
| 2/3/2026 | $117.00 | Buy | Citigroup |
| 1/30/2026 | $114.00 | Overweight | Wells Fargo |
| 1/6/2026 | Mkt Perform → Outperform | William Blair | |
| 11/19/2025 | $111.00 | Sell → Neutral | Goldman |
| 6/30/2025 | Underperform → Peer Perform | Wolfe Research |
Company also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assisted ventral hernia repair surgeriesGALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced significant milestones to unlock expanded indications for the Hugo™ robotic-assisted surgery (RAS) system in the United States and to shape the future of surgery.General surgery indication including hernia repair — 510(k) clearance submittedEmbrace Gynecology Investigational Device Exemption (IDE) clinical study — completed enrollmentGyn
Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologiesGALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies. ICE catheters provide real-time, high-resolution imaging of the heart during electrophysiology (EP) procedures for cardiac arrhythmias such as atrial fibrillation (Afib). Medtronic intends to integrate ICE into the Affera
Disciplined execution and portfolio strength position Medtronic for continued momentum into fiscal year 2027GALWAY, Ireland, June 3, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which ended April 24, 2026.Q4 Key HighlightsRevenue of $9.8 billion, increased 9.9% as reported and 6.6% organic, 90 basis points ahead of Q4 implied guidanceGAAP diluted EPS of $0.96; non-GAAP diluted EPS of $1.55, ahead of guidanceCardiac Ablation Solutions revenue increased 78% globally, including 124% U.S. growth, gaining an additional 8 points of U.S. shareCardiovascular grew 10.1%, led
8-K - Medtronic plc (0001613103) (Filer)
SD - Medtronic plc (0001613103) (Filer)
8-K - Medtronic plc (0001613103) (Filer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
Goldman resumed coverage of Medtronic with a rating of Neutral and set a new price target of $84.00
Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00
Needham upgraded Medtronic from Hold to Buy and set a new price target of $121.00
GALWAY, Ireland, March 5, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to shareholders of record at the close of business on March 27, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquarte
Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin
GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on January 16, 2026, to shareholders of record at the close of business on December 26, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea
GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent. Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu
GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)